The details behind Roche's deal with Pacific Biosciences of California.
After struggling in the years following its IPO, shares of gene sequencing specialist Pacific Biosciences of California (PACB 1.47%) jumped more than 70% yesterday after the company announced a multimillion-dollar deal with pharmaceutical company Roche (RHHBY -1.70%). In the following video, from The Motley Fool's health-care show Market Checkup, analysts Max Macaluso and David Williamson discuss the deal.
Editor's note: This video was recorded on Sept. 25, 2013.
Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical, Illumina, and Pacific Biosciences of California. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
